The Dorn Research Group focuses on the identification of novel therapeutic targets in pleural mesothelioma (PM), the thoracic cancer notorious for its lack of effective treatment options. Utilizing CRISPR functional genomics and patient-derived tumor models, we explore the function, underlying mechanisms and potential as therapeutic targets of non-oncogene dependencies in PM. Our ultimate goal is to develop molecularly targeted therapies for PM.
